SheldonJayFreedmanMDFACS

PubMed

• Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE Study).
  Steven A Kaplan, Jared L Moss, Sheldon J Freedman
  Prostate Cancer and Prostatic Diseases. 2024-09-01
• 5 citations
  The PINNACLE Study: A Double-blind, Randomized, Sham-controlled Study Evaluating the Optilume BPH Catheter System for the Treatment of Lower Urinary Tract Symptoms Sec...
  Steven A Kaplan, Jared Moss, Sheldon Freedman, Karl Coutinho, Ning Wu
  The Journal of Urology. 2023-09-01
• Reply by Authors.
  Steven A Kaplan, Jared Moss, Sheldon Freedman, Karl Coutinho, Ning Wu
  The Journal of Urology. 2023-09-01

Journal Articles

• Enzymatic Changes in Experimentally Induced Testicular Torsion.  
  Freedman, S., Chavel, M, Investigative Journal of Urology

Abstracts/Posters

• Impotence, It’s Reversible.
  Freedman, S, Southwest Impotency Center, Van Buren, AR
• A Randomized Double Blind, Placebo Controlled, At-Home Study of Intranasal Apomorphine for the Treatment of Erectile Dysfunction.
  Freedman, S, Sexual Medicine Society of North America

Lectures

• Tolterodine, an Effective and Well Tolerated Treatment for Urge Incontinence and Other Overactive Bladder Symptoms – Clinical Drug Investigation. 
• Questions about Your Urologic Health. 
  Desert Springs Hospital - Senior Advantage Group
• Enablex: A New Competitive Muscarinic Receptor Antagonist. 
  Novartis Pharmaceuticals Corporation
• Efficacy and safety of Tolterodine extended release in male patients with overactive bladder and urgency urinary incontinence. 
  Western Section AUA
• Treatment of Mixed Incontinence with Extended-Release Formulations of Oxybutynin and Tolterodine. 
  Western Section AUA
• Overactive Bladder. 
  Grand Rounds University Medical Center
• A Prospective, Randomized, Double-Blind Study of the Efficacy and Tolerability of the Extended-Release Formulations of Oxybutynin and Tolterodine: Results of the OP... 
  Western Section AUA
• Comparison of Two Treatments for Overactive Bladder in Patients Naïve to Anticholinergic Medications. 
  Western Section AUA
• Reductase Inhibitor Dutasteride Reduces the Risk of Acute Urinary Retention and Surgical Intervention in Men with Benign Prostatic Hyperplasia. 
• Detection of circulating tumor cells (CTC) in peripheral blood (PB) of prostate cancer (PC) patients (pts) by the enriched immunocytochemical (EICC) assay. 
• Sacral Nerve Stimulation as an Effective Treatment for Refractory Voiding Dysfunction. 
• Early Detection of Prostate Cancer. 
• Continuation rates with different doses of fast-dissolving desmopressin (Melt) in nocturia AUA 2010. 
• A urine based genetic assay for detection of prostate cancer in men with elevated PSA. 
• Perigee transobturator anterior prolapse repair with IntePro Polypropylene mesh: 6-month, multicenter prospective data. 
• Treatment of Overactive Bladder with Darifenacin: Analysis of Responder Rates in a 2-year Open-Label Extension Study. 
  Northeastern and New England Sections of AUA
• Efficacy and Safety of Dutasteride in the Four-Year Treatment of Men with Benign Prostatic Hyperplasia. 
• Alfuzosin Once Daily Onset of Effect in the Treatment of BPH: Randomized, Placebo-Controlled Trial Using an Acute IPSS (Alf-Acute). 
• Join now to see all